ONO-2808 for Multiple System Atrophy

Recruiting at42 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Ono Pharmaceutical Co. Ltd

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug called ONO-2808 in patients with Multiple System Atrophy (MSA). The study aims to see if the drug is safe, how it behaves in the body, and whether it can improve symptoms of MSA. Researchers are comparing three different doses of ONO-2808.

Do I have to stop taking my current medications for the trial?

The trial information does not specify if you need to stop taking your current medications. Please consult with the study team for guidance.

What data supports the idea that ONO-2808 for Multiple System Atrophy is an effective drug?

The available research does not provide specific data on the effectiveness of ONO-2808 for Multiple System Atrophy. The articles focus on other treatments, challenges in measuring outcomes, and the need for better clinical trials. There is no direct comparison or data on ONO-2808's effectiveness for this condition. ^{1 2 3 4 5}

What safety data is available for ONO-2808 in treating Multiple System Atrophy?

The provided research does not contain any safety data for ONO-2808 or its variants in the context of treating Multiple System Atrophy. The studies mentioned focus on other medications and conditions, such as COPD and asthma. ^{6 7 8 9 10}

Is the drug ONO-2808 a promising treatment for Multiple System Atrophy?

The provided research articles do not mention ONO-2808, so there is no information available to determine if it is a promising treatment for Multiple System Atrophy. ^{1 11 12 13 14}

Research Team

Project Leader

Principal Investigator

Ono Pharma USA Inc

Eligibility Criteria

This trial is for patients with Multiple System Atrophy (MSA) who can walk unassisted, have had symptoms like Parkinsonism or ataxia for no more than 5 years, and are expected to live at least another 3 years. They must be able to swallow pills and not have other serious health issues or neurological disorders besides MSA.

Inclusion Criteria

I have been diagnosed with MSA according to the latest criteria.

I can walk at least 20 steps on my own, even with a walker or cane.

Patients with an anticipated survival of at least 3 years in the opinion of the Investigator.

Exclusion Criteria

I have a liver disease or cirrhosis.

I do not have any serious health issues that could interfere with the study.

I do not have Parkinson's, dementia with Lewy bodies, or similar neurological conditions.

Treatment Details

Interventions

• ONO-2808 (Other)

Trial Overview The study tests ONO-2808 against a placebo in people with MSA. It's double-blind, meaning neither the participants nor the researchers know who gets the real drug. The goal is to check if ONO-2808 is safe and how it affects the body compared to a dummy pill.

Participant Groups

Group I: ONO-2808 Arm Experimental Treatment 1 Intervention

Group II: Placebo Arm Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

Ono Pharmaceutical Co. Ltd

Lead Sponsor

Trials

182

Recruited

97,100+

Shinji Takai

Ono Pharmaceutical Co. Ltd

Chief Medical Officer since 2023

MD from an unspecified institution

Gyo Sagara

Ono Pharmaceutical Co. Ltd

Chief Executive Officer since 2024

PhD in Pharmaceutical Sciences from Kyoto University

Findings from Research

In a double-blind, placebo-controlled crossover trial involving 8 patients with multiple-system atrophy (MSA), amantadine showed a trend towards reducing motor symptoms but did not achieve statistically significant improvements compared to placebo.

The study indicates that while amantadine may have some mild effects on motor function in MSA patients, it does not provide a clinically significant antiparkinsonian benefit, highlighting the need for further research with larger sample sizes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Placebo-controlled trial of amantadine in multiple-system atrophy. Wenning, GK.[2019]

The Unified Multiple System Atrophy Rating Scale (UMSARS) has significant limitations, including a ceiling effect that makes it difficult to detect changes in disease progression, as confirmed by data from the Natural History Study of the Synucleinopathies involving ongoing assessments.

There is a pressing need to develop and validate a new clinical outcome assessment (COA) for MSA, as the current UMSARS fails to accurately reflect disease severity and is influenced by symptomatic treatments, highlighting the importance of collaboration among clinicians, industry, and patient advocacy groups.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. Palma, JA., Vernetti, PM., Perez, MA., et al.[2022]

A cross-sectional study involving 225 patients with multiple system atrophy (MSA) utilized the unified multiple system atrophy rating scale (UMSARS) to assess the disease, highlighting the need for sensitive outcome measures for future trials.

The Japan MSA research consortium (JAMSAC) aims to conduct longitudinal studies to better understand the natural history of MSA and to develop effective therapeutic trials, emphasizing the importance of appropriate trial design and inclusion criteria.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Therapeutic trial design issues for future disease-modifying therapy of multiple system atrophy]. Ichikawa, Y., Goto, J., Nakahara, Y., et al.[2019]

Currently, there is no disease-modifying treatment for multiple system atrophy (MSA), so the focus is on a multidisciplinary approach to manage symptoms effectively.

The review highlights the latest treatment strategies for MSA and provides insights into ongoing randomized controlled trials aimed at finding new therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Symptomatic Care in Multiple System Atrophy: State of the Art. Grossauer, A., Sidoroff, V., Heim, B., et al.[2023]

In a 52-week Phase III study involving 3100 patients with moderate-to-very-severe COPD, tiotropium/olodaterol (5/5 µg) showed no increase in major adverse cardiac events or serious adverse events compared to its monocomponents, indicating its safety for older patients.

The study included a diverse age range, with 51.1% of participants under 65 and 10% aged 75 or older, demonstrating that tiotropium/olodaterol is a safe treatment option for older patients with COPD who often have multiple health issues.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies. Ferguson, GT., Maltais, F., Karpel, J., et al.[2021]

In a study of 467 adults with mild-to-moderate asthma, using a single inhaler of low-dose budesonide/formoterol significantly improved morning peak expiratory flow (PEF) compared to a higher dose of budesonide alone, with increases of 16.5 L/min versus 7.3 L/min.

The combination therapy also led to a 26% reduction in the risk of asthma exacerbations and improved the number of symptom-free days and asthma-control days, while showing similar safety profiles between the two treatment options.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Lalloo, UG., Malolepszy, J., Kozma, D., et al.[2019]

In a patient with Child A cirrhosis due to autoimmune hepatitis, serum levels of budesonide were found to be 13 times higher than in a matched control, indicating significantly increased systemic availability of the drug.

The study suggests that reduced hepatic metabolism, rather than portosystemic shunting, may be responsible for the serious side effects experienced by the patient, as evidenced by a lower ratio of drug metabolites to budesonide levels.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. Geier, A., Gartung, C., Dietrich, CG., et al.[2019]

In a 52-week study involving 708 patients with moderate to severe asthma, the combination of budesonide/formoterol showed a significantly lower rate of asthma exacerbations compared to budesonide alone, indicating improved efficacy in asthma management.

The safety profile of budesonide/formoterol was acceptable, with no significant differences in adverse events or clinical abnormalities compared to budesonide, suggesting that adding a long-acting beta(2)-adrenergic agonist (LABA) to inhaled corticosteroids (ICSs) is safe for long-term use.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. Peters, SP., Prenner, BM., Mezzanotte, WS., et al.[2022]

In a 12-month observational study involving 2539 asthma patients across eight European countries, fluticasone/formoterol was found to significantly improve asthma control, with the proportion of patients achieving controlled asthma increasing from 29.4% to 67.4%.

The safety profile of fluticasone/formoterol was consistent with previous clinical trials, with 60% of patients experiencing adverse events, but only 10.2% having events possibly related to the medication, indicating it is generally safe for long-term use.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management. Backer, V., Ellery, A., Borzova, S., et al.[2019]

Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder characterized by the accumulation of aggregated alpha-synuclein in oligodendrocytes, leading to significant motor and autonomic dysfunction.

Current treatments for MSA focus on symptom management, but there is a critical need for neuroprotective or disease-modifying therapies, as the underlying mechanisms of alpha-synuclein aggregation remain poorly understood.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Multiple System Atrophy - State of the Art. Laurens, B., Vergnet, S., Lopez, MC., et al.[2018]

In a study involving PLP-α-syn transgenic mice, treatment with ATH434 for 6 months preserved motor performance and protected against neuron loss, indicating its potential as a disease-modifying therapy for multiple system atrophy (MSA).

ATH434 treatment led to a significant reduction in α-synuclein aggregates and oligomers, increased microglial lysosomal activity, and lower iron levels in the substantia nigra, suggesting a mechanism of action that enhances α-syn clearance without increasing inflammation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

ATH434 Reduces α-Synuclein-Related Neurodegeneration in a Murine Model of Multiple System Atrophy. Heras-Garvin, A., Refolo, V., Schmidt, C., et al.[2022]

In a study of 46 patients suspected of having multiple system atrophy (MSA) in Singapore, 72% were confirmed to meet the diagnostic criteria, with a predominance of MSA-C cases and a mean age of onset at 60 years.

The study found that after 3 years, 31% of patients required assistance for walking and 17% needed a wheelchair, with these rates increasing to 45% and 30% by 5 years, indicating significant disease progression over time.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical characteristics of patients with multiple system atrophy in Singapore. Jamora, RD., Gupta, A., Tan, AK., et al.[2020]

References

1. United States pubmed.ncbi.nlm.nih.gov

Placebo-controlled trial of amantadine in multiple-system atrophy. [2019]

2. Germany pubmed.ncbi.nlm.nih.gov

Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. [2022]

3. Japan pubmed.ncbi.nlm.nih.gov

[Therapeutic trial design issues for future disease-modifying therapy of multiple system atrophy]. [2019]

4. United States pubmed.ncbi.nlm.nih.gov

Symptomatic Care in Multiple System Atrophy: State of the Art. [2023]

5. United States pubmed.ncbi.nlm.nih.gov

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. [2021]

6. England pubmed.ncbi.nlm.nih.gov

Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies. [2021]

7. United States pubmed.ncbi.nlm.nih.gov

Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. [2019]

8. United States pubmed.ncbi.nlm.nih.gov

Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. [2019]

9. United States pubmed.ncbi.nlm.nih.gov

Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. [2022]

10. England pubmed.ncbi.nlm.nih.gov

Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management. [2019]

11. United States pubmed.ncbi.nlm.nih.gov

Multiple System Atrophy - State of the Art. [2018]

12. Switzerland pubmed.ncbi.nlm.nih.gov

Diagnostic Effectiveness of [123I]Ioflupane Single Photon Emission Computed Tomography (SPECT) in Multiple System Atrophy. [2023]

13. United States pubmed.ncbi.nlm.nih.gov

ATH434 Reduces α-Synuclein-Related Neurodegeneration in a Murine Model of Multiple System Atrophy. [2022]

14. Singapore pubmed.ncbi.nlm.nih.gov

Clinical characteristics of patients with multiple system atrophy in Singapore. [2020]